Hazen Tuck, MD
Pulmonary Disease · Janesville, WINPI 1124225487
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,015 of the $6,601 with a category attached, or 60.8%. Intuitive Surgical accounts for 79.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $5,257 and has fallen 99.4% since, to $32 in 2025.
Across 87 payments — averaging $75.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Amgen$355
- AstraZeneca$277
- Sunovion Pharmaceuticals Inc.$127
- Boehringer Ingelheim$94
- GSK$83
- plus $399 from 13 others
What the payments were for
- Travel & lodging$1,23519%
- Food & beverage$1,35120%
- Education$4,01561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $5,267 |
| Amgen | 27 | $355 |
| AstraZeneca | 10 | $277 |
| Sunovion Pharmaceuticals Inc. | 10 | $127 |
| Boehringer Ingelheim | 6 | $94 |
| GSK | 5 | $83 |
| Sanofi-aventis U.S. LLC | 4 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Pfizer | 3 | $53 |
| Shire North American Group Inc | 2 | $39 |
| Grifols USA, LLC | 2 | $31 |
| Novartis | 2 | $28 |
| Sanofi | 1 | $24 |
| Mylan Specialty L.p. | 1 | $20 |
| Insmed, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Merck | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,205
- FASENRA$126
- SYMBICORT$126
- FARXIGA$126
How this compares
$6,601 in reported general payments places this provider in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 532 | $426,420 |
| Tyvaso DpiTreprostinil | 11 | $257,683 |
| Breo ElliptaFluticasone/Vilanterol | 529 | $257,513 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 295 | $166,351 |
| Spiriva HandihalerTiotropium Bromide | 191 | $122,649 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $116,956 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 285 | $107,368 |
| OfevNintedanib Esylate | 12 | $98,641 |
| SymbicortBudesonide/Formoterol Fumarate | 270 | $88,587 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 137 | $82,039 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 261 | $52,675 |
| Incruse ElliptaUmeclidinium Bromide | 110 | $43,727 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,354 | $40,532 |
| Tiotropium Bromide | 39 | $38,526 |
| Spiriva RespimatTiotropium Bromide | 46 | $37,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $83 | $930,7671,599 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $94 | $245,253245 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $277 | $120,514333 claims |
| Grifols USA, LLCProlastin C | $31 | $116,95612 claims |
| MerckDulera | $13 | $22,68947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Janesville
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.